## Abstract Despite improvements in chemotherapy and surgery in the treatment of osteosarcoma (OS), satisfactory results are still difficult to achieve. Novel therapeutic modalities need to be developed for osteosarcoma treatment. The combined effects of tumor necrosis factor‐related apoptosis‐indu
α-TEA induces apoptosis of human breast cancer cells via activation of TRAIL/DR5 death receptor pathway
✍ Scribed by Weiping Yu; Richa Tiwary; Jing Li; Sook-Kyung Park; Li Jia; Ailian Xiong; Marla Simmons-Menchaca; Bob G. Sanders; Kimberly Kline
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 343 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0899-1987
- DOI
- 10.1002/mc.20681
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Vitamin E derivative RRR‐α‐tocopherol ether‐linked acetic acid analog (α‐TEA) induces apoptosis in MCF‐7 and HCC‐1954 human breast cancer cells in a dose‐ and time‐dependent manner. α‐TEA induces increased levels of tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) and death receptor‐5 (DR5) and decreased levels of antiapoptotic factor, cellular FLICE‐like inhibitory protein (c‐FLIP L). DR5/TRAIL induced apoptosis involves downregulation of c‐FLIP (L), caspase‐8 activation, activated proapoptotic mediators tBid and Bax, mitochondrial permeability transition, and activation of caspase‐9. siRNA knockdown of either DR5 or TRAIL blocks the ability of α‐TEA to enhance DR5 protein levels, downregulate c‐FLIP(L) protein levels and induce apoptosis. Combination of α‐TEA + TRAIL acts cooperatively to induce apoptosis, and increase DR5 and decrease c‐FLIP (L) protein levels. siRNA knockdown of c‐FLIP produces a low level of spontaneous apoptosis and enhances α‐TEA‐ and TRAIL‐induced apoptosis. Taken together, these studies show that α‐TEA induces TRAIL/DR5 mitochondria‐dependent apoptosis in human breast cancer cells, and that TRAIL/DR5‐dependent increases in DR5 and decreases in c‐FLIP expression are triggered by TRAIL or α‐TEA treatments. © 2010 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
While TRAIL is relatively non-toxic to normal cells, it can selectively induce apoptosis in many types of transformed cells. Nevertheless, some non-small cell lung cancer (NSCLC) cells are particularly resistant to the effects of TRAIL. Here, we report that in combination with naringenin exposure to
## Abstract Thrombosis is a major complication and an important cause of death in cancer patients. Tumor cells may trigger coagulation and induce a prothrombotic phenotype, which in return may enhance angiogenesis, tumor growth, and metastasis. Tissue factor pathway inhibitor (TFPI) has been report
## Abstract __Glycyrrhiza uralensis__ (licorice) is one of the most frequently prescribed ingredients in Oriental medicine, and licorice extract has been shown to exert anti‐carcinogenic effects. However, its use as a cancer chemopreventive agent is rather limited, due to the fact that its principa
## Abstract Overexpression of the interleukin‐2 receptor (IL‐2R) α chain in tumor cells is associated with tumor progression and a poor patient prognosis. IL‐2Rα is responsible for the high affinity binding of the receptor to IL‐2, leading to activation of several proliferative and anti‐apoptotic i
## Abstract ## BACKGROUND. The tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) death receptor, DR5, mediates proapoptotic signals and is implicated in the pathogenesis of many neoplasms including nonsmall‐cell lung cancer (NSCLC). ## METHODS. In this study, immunohistochemical ex